Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn’t designed with them in mind.
-
Myriad Genetics will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. Webcast at investor.myriad.com.
-
Myriad Genetics will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting.
-
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of...
-
Myriad will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting April 10-13, including two oral presentations and two posters.
-
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
-
Myriad Genetics announces the launch of the Precise MRD test with a select number of oncology practices for patients with breast cancer.
-
Data presented at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests.
-
Myriad Genetics reports fourth quarter and full-year 2025 financial results; reiterates 2026 financial guidance reflecting strengthened execution.
-
Myriad Genetics announced the publication of the analytical validation of the FirstGene® Multiple Prenatal Screen in Clinical Chemistry.